Ann: Neurotech Completes $9.0M Placement, page-22

"the 20 week results just weren’t strong enough ... so interpret the results how you want"

Well, for what it's worth, my interpretation is that the results were very strong off the back of the initial results announced 28-Jul. Given that the initial results were particularly strong (93% subjects improved, 64% much improved) it seems a bit unreasonable to expect further improvement in the longer trial. NTI-64 isn't curing the condition, it's moderating the symptoms. Therefore I see two key takeaways from these studies:

1. NTI-64 is rapidly effective, and its effectiveness doesn't decline over time.
2. There are no adverse effects (so far) that would prevent continuous treatment.

I see the share price action as more reflective of the company's conduct in relation to its holders:

• If you're an institutional or sophisticated investor you don't really need to buy on market. You can just wait for the company to hand out a juicy deal next time it needs some cash.
• If you're a retail investor there's not much point trying to get involved unless the price is at a serious discount to fair value because you know the company isn't going to give you much recognition for your involvement.